<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00505232</url>
  </required_header>
  <id_info>
    <org_study_id>GELTAMO-LCM-04-02</org_study_id>
    <secondary_id>2005-004400-37</secondary_id>
    <nct_id>NCT00505232</nct_id>
  </id_info>
  <brief_title>Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)</brief_title>
  <acronym>LCM-04-02</acronym>
  <official_title>Induction Treatment With Anti-CD20 Plus Hyper-CVAD and Methotrexate/Cytarabine Followed by Consolidation Treatment With Y90 Ibritumomab-Tiuxetan in Patients With Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CABYC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CABYC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mantle Cell Lymphoma (MCL) is a malignancy with a poor response to treatment and with a
      median survival of 2- 4 years since diagnosis. Although histology is similar to that of an
      indolent lymphoma, MCL is currently considered an aggressive tumour. Few prospective
      therapeutic trials have been reported in MCL, and results are difficult to interpret due to
      treatment heterogeneity. It is known that standard chemotherapy for other clinically
      aggressive lymphomas yields poor results. Recently, better results have been communicated
      with intense induction chemotherapy treatments or consolidating the response with high dose
      chemotherapy with stem cell support. Keeping in mind these considerations, we will use and
      intensive induction treatment with Hyper-CVAD/MTX-AraC associated with anti-CD20 in order to
      increase the overall response rate followed by consolidation treatment with Ibritumomab
      -tiuxetan (Zevalin) with the aim of eradicate the minimal residual disease, responsible of
      relapse.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:

        -  The Patients will receive 6 cycles of induction chemotherapy as follows: Anti-CD20/Hyper
           -CVAD chemotherapy will be alternated with anti-CD20 +MTX/Ara-C chemotherapy. After 4
           cycles (2 x2), response will be evaluated. If response (complete or partial) is
           observed, 2 additional cycles will be administrated. If less than a partial response is
           observed, the patient will be out of the study.

        -  Consolidation treatment will be a single dose of Y90Ibritumomab -Tiuxetan (Zevalin) will
           be administered after 12 weeks after completion of induction chemotherapy. The initial
           dose of Zevalin will be 0.3 mCi/kg, to be further escalated to 0.4 mCi/Kg if
           unacceptable toxicity does not occur.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment safety</measure>
    <time_frame>36 months</time_frame>
    <description>Safety of the treatment, recording the adverse events throughout the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility of proposed treatment scheme.</measure>
    <time_frame>36 months</time_frame>
    <description>Number and percentage of patients susceptible of receiving consolidation treatment after induction chemotherapy, according to inclusion criteria for consolidation with radioinmunotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy based on response rate: overall, partial and complete response.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free, disease free and overall survivals.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the significance of the minimal residual disease (MRD) detection.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Rituximab-HCVAD,Methotrexate/Cytarabine and Zevalin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction Treatment (Rituximab-HCVAD and Methotrexate/Cytarabine) followed by Consolidation Treatment (Rituximab and Y-90 Ibritumomab tiuxetan)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Y-90 Ibritumomab tiuxetan</intervention_name>
    <description>Study Design
The present study will be split into two cohorts:
Patients younger than 60 years who will receive 8 chemotherapy cycles
Patients older than 60 years who will receive 6 chemotherapy cycles
The induction schema summarises as follows :
Anti-CD20/Hyper -CVAD chemotherapy will be alternated with anti-CD20 +MTX/Ara-C chemotherapy twice. Afterward, response will be evaluated, followed by, either, four cycles further patients younger than 60 years who will obtain a CR or PR, or 2 cycles patients older than 60 y. (see figure 1 and flow chart).
Consolidation treatment will consist in a single dose of Y90-Ibritumomab -Tiuxetan (Zevalin) [0.4 mCi/Kg b.w or 0.3 mCi/kg if platelets &lt; 100,000/µl] will be administered 8 to 12 weeks after last chemotherapy.</description>
    <arm_group_label>Rituximab-HCVAD,Methotrexate/Cytarabine and Zevalin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All histologic MCL subtypes (WHO classification)

          -  Age between 18 and 70 years old

          -  Performance status 0 to 2 (ECOG)

          -  Cardiac ejection fraction &gt;50%

          -  Adequate organ (hepatic, cardiac and renal) and marrow function: Hb&gt; 10g/dl,
             neutrophil counts&gt; 1500/ µl, platelet&gt; 100000/ µl. Creatinine &lt; 2,5xULN, bilirubin,
             AST or ALT&lt;2,5xULN.

          -  For Y90-ibritumomab tiuxetan administration: Bone Marrow Infiltration by lymphoma
             cells &lt; than 25% ; platelet count &gt;100,000/µl and neutrophil counts &gt;1500/µl

          -  Informed consent should be obtained

        Exclusion Criteria:

          -  Ann Arbor stages I or II without B symptoms or bulky disease (&gt;10 cm).

          -  Previous chemotherapy or radiotherapy treatment.

          -  Uncontrolled current illness: Hepatic, renal, cardiovascular, neurological or
             metabolic illness.

          -  Symptomatic congestive heart failure, unstable angina pectoris, clinically significant
             cardiac arrhythmia.

          -  HIV, HBV or HCV positive serology.

          -  Limitation of the patient´s ability to comply with the treatment or follow-up
             protocol.

          -  Men and women with reproductive potential who are not using effective contraceptive
             methods during and at least 12 months after the end of the study

          -  Acute or chronic active infection.

          -  Known hypersensitivity to some of the drugs or other related compounds

          -  No informed consent obtained
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reyes Arranz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital La Princesa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de Valencia</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galica</state>
        <zip>15705</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ruber</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Moncloa</name>
      <address>
        <city>Madrid</city>
        <zip>28008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <zip>28035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Quiron</name>
      <address>
        <city>Madrid</city>
        <zip>28224</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2007</study_first_submitted>
  <study_first_submitted_qc>July 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2007</study_first_posted>
  <last_update_submitted>December 30, 2011</last_update_submitted>
  <last_update_submitted_qc>December 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Y-90 Ibritumomab tiuxetan</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Hyper-CVAD</keyword>
  <keyword>Mantle Cell Lymphoma Patients</keyword>
  <keyword>Zevalin(R)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

